Navigation Links
The Lupus Foundation of America Seeks Applications for its 2010 Gina M. Finzi Memorial Student Summer Fellowship Program
Date:1/12/2010

WASHINGTON, Jan. 12 /PRNewswire-USNewswire/ -- The Lupus Foundation of America, Inc. (LFA) is seeking applications for its 2010 Gina M. Finzi Memorial Student Summer Fellowship Program.  The purpose of these awards is to foster an interest among young investigators in lupus research under the supervision of an established investigator.  Undergraduate, graduate, and medical students are eligible to apply; however, preference is given to students with a college degree.

It has been 50 years since the U.S. Food and Drug Administration (FDA) has approved a drug for lupus. The Gina M. Finzi Memorial Student Summer Fellowship Program is part of the LFA's National Research Program, Bringing Down the Barriers, which seeks to advance the science and medicine of lupus and bring down the barriers that have obstructed lupus research in the past.

Named after the daughter of former LFA President Emeritus Dr. Sergio Finzi, the Gina M. Finzi Memorial Student Summer Fellowship Program has supported the work of approximately 200 young investigators since it was founded in 1984. The purpose of these grants is to accelerate research related to the causes, treatments, prevention and cure of lupus, as well as to directly sponsor research focused on testing new approaches and developing experimental therapies or treatments.

The amount of the award is $2,000, and applications are due no later than 5:00 p.m. EST on March 5, 2010. The expected notification date is May 5, 2010. To learn more about the Gina M. Finzi Memorial Student Summer Fellowship Program, and download application guidelines, visit www.lupus.org/finzifellowships.

The LFA uses an electronic grants submission process. All interested grant applicants must submit their full application packages through proposalCENTRAL: https://proposalcentral.altum.com/Login.asp. Applicants are encouraged to register and complete a professional profile at proposalCENTRAL as soon as possible. Applicants should ensure that their grants and contracts office has registered their institution, financial, and signing officials with proposalCENTRAL.

A proposalCENTRAL helpline is available for questions from applicants during normal business hours 8:30 a.m.5:30 p.m., Monday-Friday, EST. Call toll-free 1-800-875-2562. You can also send an email to pcsupport@altum.com.

About Lupus

Lupus is an acute and chronic autoimmune disease in which the immune system is unbalanced, causing inflammation and tissue damage to virtually any organ in the body. Its health effects include heart attacks, strokes, seizures, miscarriages, and organ failure. Ninety percent of the people with lupus are women, and it is two to three times more common among African Americans, Hispanics/Latinos, Native Americans, and Asians.  Lupus is unpredictable and potentially fatal, yet at present no satisfactory treatment or cure exists.

About the LFA

The LFA is the foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affected by lupus. Founded in 1977, the LFA has a nationwide network of nearly 300 chapters and support groups and operates programs of research, education, and advocacy.

SOURCE Lupus Foundation of America

RELATED LINKS
http://www.lupus.org

'/>"/>

SOURCE Lupus Foundation of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Twins Provide Clues to Lupus
2. 2009: A Year of Many Firsts in Efforts to Overcome Lupus
3. Julian Lennon and James Scott Cook Release New Charity Single LUCY to Raise Awareness and Funds for Lupus Research
4. Washington Lupus Chapter Celebrates 35th Anniversary on December 5
5. New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel
6. Kidney transplants generally safe for lupus patients
7. Scientists Find New Key to Lupus
8. Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice
9. National Report Shines Light on Lupus 50-Year Treatment Drought
10. The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM)
11. Lupus Worse in Blacks, Hispanics Than in Whites, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director ... Communication of Education Research Award. The award honors scholars exemplary in their capacity ... a scholar who has demonstrated the capacity to deepen the public’s understanding and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
Breaking Medicine Technology: